Fig. 3From: How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directionsGraphically presented roadmap to a new therapeutic era of oral anti-TNF-α therapy (own drawing). anti-TNF-α anti-tumor necrosis factor-alpha, mAb monoclonal antibody, LNPs lipid nanoparticlesBack to article page